Embla Medical hf: Interim Report Q3 2026
Announcement no. 51/2026 Interim Report Q3 2026 Sveinn Sölvason, President and CEO, comments: “Sales in Q3 2026 were USD 250 million, representing 5% reported growth and 4% organic growth. Growth was driven by Prosthetics & Neuro Orthotics, with strong performance in EMEA, partially offset by softer results in Americas…
Short extract only — this publisher licenses its text. Read the full release at the source.
Free plan · Plus CA$29 or Pro CA$99/month


